Novel treatment of inflammatory diseases LipUm
improved treatment
novel treatment of rheumatoid arthritis
children
orphan drug designation
health economic calculations
inflammatory process
serious diseases
disease onset
drugs
biologicals
patients
unique therapeutic antibody
World Health Organisation
adverse health effects
global prevalence of RA
drug market value growth
total cost
key target
juvenile idiopathic arthritis
complementary therapeutic mechanism
societal economic burden
Key opinion leaders
extreme disability
full-time job
major achievement
TNF-alfa inhibitors
Bile Salt-Stimulated Lipase
poor quality of life
developed countries
years
risk
woman
need
joint destruction
immune system
pharmaceuticals
condition
experience
transient improvement
tentative strategy
Europe
age
immunosuppressants
introduction
gap
USD